PMID- 36589830
OWN - NLM
STAT- MEDLINE
DCOM- 20230103
LR  - 20230127
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Serum spexin differed in newly diagnosed type 2 diabetes patients according to 
      body mass index and increased with the improvement of metabolic status.
PG  - 1086497
LID - 10.3389/fendo.2022.1086497 [doi]
LID - 1086497
AB  - OBJECTIVE: The aim of this study was to explore serum spexin levels in newly 
      diagnosed type 2 diabetes mellitus (T2DM) patients with different body mass 
      indexes (BMIs) and to investigate the changes of spexin after improvement of 
      metabolic indicators. METHODS: A total of 323 newly diagnosed T2DM patients from 
      national Metabolic Management Center (MMC) in Shanghai General Hospital were 
      recruited. T2DM patients were categorized into three groups: diabetes with 
      obesity group (DM-OB group, BMI>/=28 kg/m(2), n=89), diabetes with overweight group 
      (DM-OV group, 24</=BMI<28 kg/m(2), n=161), and diabetes with normal weight group 
      (DM-NW group, 18</=BMI<24 kg/m(2), n=73). In addition, 41 volunteers with normal 
      glucose tolerance (NGT) were used as controls. Spexin and metabolic parameters 
      were compared at baseline, and changes after MMC follow-up in 100 DM patients 
      were investigated. RESULTS: In the DM-OB group, the level of spexin was 
      significantly lower than that in the DM-OV group and the DM-NW group (P < 0.01). 
      Spexin was significantly negatively related to body mass index (BMI, beta=-0.214, 
      P<0.001), waist circumference (beta=-0.249, P<0.001), visceral fat area (VFA, 
      beta=-0.214, P<0.001), and subcutaneous fat area (SFA, beta=-0.265, P<0.001) after 
      adjustment for age and sex. Among all the metabolic indicators, the decline in 
      BMI in the DM-OB group was the most obvious among those in the three groups (-3.7 
      +/- 0.8 kg/m(2) vs. -0.9 +/- 0.3 kg/m(2) vs. 0.7 +/- 0.6 kg/m(2), P<0.01) after one 
      year of MMC standardized management. The serum spexin level in the DM-OB group 
      increased the most (1.00 +/- 0.10 ng/mL vs. 0.49 +/- 0.06 ng/mL in DM-OV group and 
      0.58 +/- 0.09 ng/mL in DM-NW group, P < 0.001). CONCLUSIONS: Serum spexin differed 
      in newly diagnosed T2DM patients according to BMI and was lowest in the DM-OB 
      group. With the improvement of metabolic indicators, especially the decline in 
      BMI, serum spexin increased significantly after MMC management.
CI  - Copyright (c) 2022 Gu, Yan, Huang, Yang, Peng and Wang.
FAU - Gu, Liping
AU  - Gu L
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Yan, Shuai
AU  - Yan S
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Huang, Yunhong
AU  - Huang Y
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Yang, Jiaying
AU  - Yang J
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Peng, Yongde
AU  - Peng Y
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Wang, Yufan
AU  - Wang Y
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221214
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - Body Mass Index
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - China/epidemiology
MH  - Obesity/metabolism
MH  - Overweight
PMC - PMC9794602
OTO - NOTNLM
OT  - metabolic management centre
OT  - newly diagnosed type 2 diabetes
OT  - obesity
OT  - overweight
OT  - spexin
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/03 06:00
MHDA- 2023/01/04 06:00
PMCR- 2022/01/01
CRDT- 2023/01/02 04:09
PHST- 2022/11/01 00:00 [received]
PHST- 2022/11/28 00:00 [accepted]
PHST- 2023/01/02 04:09 [entrez]
PHST- 2023/01/03 06:00 [pubmed]
PHST- 2023/01/04 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.1086497 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Dec 14;13:1086497. doi: 
      10.3389/fendo.2022.1086497. eCollection 2022.